BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Strayer DR, Young D, Mitchell WM. Effect of disease duration in a randomized Phase III trial of rintatolimod, an immune modulator for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. PLoS One 2020;15:e0240403. [PMID: 33119613 DOI: 10.1371/journal.pone.0240403] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Renz-polster H, Tremblay M, Bienzle D, Fischer JE. The Pathobiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: The Case for Neuroglial Failure. Front Cell Neurosci 2022;16:888232. [DOI: 10.3389/fncel.2022.888232] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Ramiller A, Mudie K, Seibert E, Whittaker S. The Facilitation of Clinical and Therapeutic Discoveries in Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome and Related Diseases: A Protocol for the You + ME Registry Research Platform (Preprint). JMIR Research Protocols. [DOI: 10.2196/36798] [Reference Citation Analysis]
3 Putilina MV. [Asthenic disorders as a manifestation of chronic fatigue syndrome]. Zh Nevrol Psikhiatr Im S S Korsakova 2021;121:125-30. [PMID: 34481448 DOI: 10.17116/jnevro2021121081125] [Reference Citation Analysis]
4 Araja D, Berkis U, Lunga A, Murovska M. Shadow Burden of Undiagnosed Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) on Society: Retrospective and Prospective-In Light of COVID-19. J Clin Med 2021;10:3017. [PMID: 34300183 DOI: 10.3390/jcm10143017] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
5 Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Lond) 2021;53:737-54. [PMID: 34024217 DOI: 10.1080/23744235.2021.1924397] [Cited by in Crossref: 6] [Cited by in F6Publishing: 118] [Article Influence: 6.0] [Reference Citation Analysis]
6 Stanculescu D, Larsson L, Bergquist J. Theory: Treatments for Prolonged ICU Patients May Provide New Therapeutic Avenues for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Front Med (Lausanne) 2021;8:672370. [PMID: 34026797 DOI: 10.3389/fmed.2021.672370] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
7 Dafoe W. Extremely Severe ME/CFS-A Personal Account. Healthcare (Basel) 2021;9:504. [PMID: 33925566 DOI: 10.3390/healthcare9050504] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]